Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer(IDEAL Stage 2b)
NCT06788548 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 312
Last updated 2026-05-11
Summary
The main treatment for early gastric cancer (EGC) include endoscopic submucosal dissection (ESD) and radical gastrectomy. However, appropriate treatment for patients who exceed the absolute indications and noncurative resection of ESD remains unestablished. Sentinel node navigation surgery (SNNS) enables limited lymph node resection, thereby facilitating function-preserving gastrectomy (FPG) and improving quality of life (QoL). SNNS seems to be the promising solution according to previous study, however evidence-based medicine was lacking. It is imperative to establish its safety and efficacy in patients with EGC. However, the optimal implementation of FPG remain unclear. Moreover, objective assessment of postoperative functional outcomes,remains limited.
Conditions
- Early Gastric Cancer
Interventions
- PROCEDURE
-
Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery
Patients without prior ESD received ESD with laparoscopic sentinel basin dissection (LSBD) for ESD resectable lesions, otherwise patients received laparoscopic-endoscopic cooperative regional gastrectomy (LRG) with LSBD. For patients with prior non-curative ESD, LSBD alone was performed if margins were negative, otherwise LRG with LSBD was conducted. Intraoperative frozen-section pathological examination of the horizontal resection margin of the ESD or full-thickness specimen. During laparoscopic sentinel node basin dissection (LSBD), indocyanine green (ICG) (2 mL, 2.5 mg/mL) was endoscopically injected into the submucosal layer at four quadrants around the marking points (0.5 mL per quadrant). Fifteen minutes after ICG injection, sentinel lymph node basins (SLBs) were defined as the area within a 2 cm margin of the detected fluorescence stained nodes, which were marked with laparoscopic clips.
- PROCEDURE
-
Laparoscopic D2 radical gastrectomy
Preparation: The patient is positioned supine with general anesthesia. An orogastric tube and Foley catheter are inserted. Antibiotics are administered, and sequential stockings are applied. Port Placement: Pneumoperitoneum is created via a Veress needle at the umbilicus. Working ports are placed in the upper quadrants, with a fifth port for liver retraction. Abdominal Exploration: The abdomen is inspected for metastases, and peritoneal cytology is performed. Dissection and Lymph Node Removal: The lesser omentum is divided near the liver, reaching the cardia and diaphragm. The gastrocolic ligament is divided along the transverse colon. Lymph node dissection begins along the splenic artery, then proceeds to the left gastric artery and celiac nodes. The left gastric vessels are controlled with endoclips.After lymph node dissection, distal subtotal gastrectomy is performed. Digestive tract reconstruction is typically done through a mini-laparotomy.
Sponsors & Collaborators
-
China-Japan Friendship Hospital
collaborator OTHER -
Cancer Hospital Chinese Academy of Medical Scienc
collaborator UNKNOWN -
Beijing Friendship Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-02-03
- Primary Completion
- 2029-11-01
- Completion
- 2029-12-30
Countries
- China
Study Locations
More Related Trials
-
Randomized Controlled Trials Comparing Clinical Outcomes of 3D Versus 2D Laparoscopic Surgery for Gastric Cancer
NCT02327481 ·Status: COMPLETED ·Phase: NA
-
Robot-assisted D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
NCT05728606 ·Status: UNKNOWN ·Phase: NA
-
Total Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer
NCT04795063 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection
NCT02572050 ·Status: UNKNOWN ·Phase: PHASE2
-
Verifying the Specificity of a New Method in Predicting Lymph Node Metastasis in Early Gastric Cancer Patients
NCT03632746 ·Status: UNKNOWN
-
Exploratory Study of Single-port Robot-assisted Gastrectomy
NCT06201585 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
NCT03468712 ·Status: UNKNOWN ·Phase: NA
-
Phase III Study OF the Gastric Surgery on Advanced Stage Gastric Cancer
NCT00260884 ·Status: COMPLETED ·Phase: PHASE3
-
Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy
NCT06895447 ·Status: RECRUITING ·Phase: PHASE2
-
The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer
NCT07183150 ·Status: RECRUITING
-
Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer
NCT04050787 ·Status: UNKNOWN ·Phase: NA
-
Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer
NCT06791538 ·Status: RECRUITING ·Phase: NA
-
3D Versus 2D Laparoscopic Total Gastrectomy With Splenic Hilum Lymph Nodes Dissection
NCT02984787 ·Status: UNKNOWN ·Phase: PHASE3
-
Phase II Study for Robot Assisted Distal Gastrectomy
NCT01504997 ·Status: UNKNOWN ·Phase: PHASE2
-
Function Preserving Gastrectomy for T1/2 Gastric Cancer Patients
NCT03874871 ·Status: UNKNOWN
-
A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
NCT04440605 ·Status: UNKNOWN
-
Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
NCT02845986 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer
NCT04062058 ·Status: UNKNOWN ·Phase: PHASE2
-
A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer
NCT02144727 ·Status: UNKNOWN ·Phase: PHASE3
-
A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant Chemotherapy
NCT02404753 ·Status: UNKNOWN ·Phase: PHASE2
-
Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer
NCT03961373 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy
NCT07056010 ·Status: RECRUITING ·Phase: NA
-
Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. Chemoradiotherapy
NCT03680261 ·Status: UNKNOWN ·Phase: PHASE3
-
The Possible Range of No.12a Lymph Node Dissection of Locally Advanced Gastric Cancer
NCT06033482 ·Status: UNKNOWN
-
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
NCT02004769 ·Status: COMPLETED ·Phase: PHASE2